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Abstract 
Abdominal fat-related activation of the innate immune system and insulin resistance (IR) are implicated in 
the pathogenesis of cardiovascular diseases. Recent data support an important role of the adaptive 
immune system as well. In this study, we investigate the association between waist circumference and 
markers of systemic adaptive immune activation, and the potential mediating role of innate immune 
activation and/or IR herein. The study population consisted of 477 (304 men) individuals (mean age: 
59.4±7.0 years) in whom waist circumference, HOMA2-IR (IR derived from homeostasis model 
assessment), and markers of innate (C-reactive protein (CRP), interleukin (IL)-6, serum amyloid A (SAA)) 
and adaptive (neopterin, soluble CD25 (sCD25)) immune activation were measured. These markers were 
compiled into an adaptive and innate immune activation score by averaging the respective z-scores. After 
adjustments for age, sex, glucose metabolism, smoking status, prior cardiovascular disease, and other 
risk factors, waist circumference was associated with the adaptive (standardized regression coefficient Β 
= 0.12 (95% confidence intervals: 0.04-0.20)) and the innate immune activation scores (Β = 0.24 
(0.17-0.31)), and with HOMA2-IR (Β = 0.49 (0.42-0.56)). The innate immune activation score and 
HOMA2-IR were also positively associated with the adaptive immune activation score (Β = 0.31 
(0.21-0.40) and Β = 0.11 (0.02-0.21), respectively). The association between waist circumference and the 
adaptive immune activation score was completely abolished when further adjusted for innate immune 
activation and HOMA2-IR (to Β = 0.01 (0.10-0.08)), and the specific mediation effects attributable to each 
of these variables were 58% and 42%, respectively. We conclude that abdominal obesity is associated 
with systemic adaptive immune activation and that innate immune activation and IR constitute 
independent and equally important pathways explaining this association. 2011 The Obesity Society. 
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IntroductIon
Obesity, in particular abdominal obesity, increases the risk of 
several chronic diseases such as hypertension, diabetes, and 
cardiovascular diseases (1). Although the underlying patho-
physiological mechanisms explaining these associations have 
not been completely unraveled, chronic low-grade inflamma-
tion and insulin resistance (IR), which are intertwined, are 
thought to play a key role in these (abdominal) obesity-related 
complications (2–5).
Inflammation associated with excessive abdominal fat mass 
starts locally in the adipose tissue (6). With increasing obesity, 
proinflammatory macrophages accumulate in adipose tissue 
(7). Adipose tissue macrophages are responsible for almost all 
adipose tissue tumor necrosis factor-α and contribute signifi-
cantly to adipose tissue–derived interleukin-6 (IL-6) (7), mol-
ecules involved in systemic IR (8,9). Although research so far 
has focused mainly on innate immune mechanisms and mark-
ers of obesity-related inflammation, recent observations have 
drawn some attention to the role of adaptive immune mecha-
nisms in obesity and related sequelae. Indeed, accumulation of 
adaptive immune cells, such as T cells, has been demonstrated 
in adipose tissue in obesity (10,11). Moreover, several recent 
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studies suggest that T lymphocytes are crucially involved in 
the initiation and maintenance of adipose tissue inflammation 
and systemic IR (11–14). It should be noted that most of these 
data were obtained in mouse models of obesity and focused 
on the local inflammatory process in adipose tissue. However, 
the extent to which these mechanisms translate to humans 
and are operable at the systemic level is largely unknown. To 
that aim, investigating associations of (central) obesity with 
markers discerning between the innate and adaptive immune 
activation, as well as the role of IR herein, may thus enable a 
better understanding of these mechanisms. Macrophages are 
a major source of circulating IL-6 (7), which induces hepatic 
production of acute phase reactants such as C-reactive pro-
tein (CRP) and serum amyloid A (SAA). The levels of these 
molecules are commonly used as markers of activation of 
the innate immune system (15). On the other hand, levels of 
soluble CD25 (sCD25) and neopterin can be considered as 
markers of adaptive immune activation. Production of the 
soluble IL-2 receptor (sCD25) is associated with T-cell activa-
tion in vitro (16,17). In addition, increased serum sCD25 levels 
have been associated with lymphocyte activation in infection, 
autoimmune diseases and hematologic malignancies (18–20). 
Neopterin, a product of interferon-γ–activated monocytes/
macrophages is a sensitive indicator of cell-mediated immune 
activation. In humans, increased concentrations of neopterin 
in serum and urine have been found during allograft rejection 
episodes and in various malignant disorders, autoimmune dis-
eases, and viral infections (21).
In view of these considerations, we have examined, in a large 
cohort of individuals at increased risk of diabetes and cardio-
vascular disease: (i) whether waist circumference, a surrogate 
marker of abdominal fat mass (22), is associated with adaptive 
immune activation, as characterized by elevations in neopterin 
and sCD25, and (ii) the extent to which any such associations 
are explained, i.e., are potentially mediated, by innate immune 
activation and/or IR.
Methods and Procedures
subjects and study design
We used data from the Cohort of Diabetes and Atherosclerosis 
Maastricht Study, an ongoing prospective cohort study in the 
Netherlands that was originally designed to study the effects of obesity, 
glucose tolerance, lipid metabolism, lifestyle and genetics on cardiovas-
cular complications, and that has been described in detail elsewhere 
(23,24). Briefly, between 1999 and 2001 subjects were selected from a 
large population-based cohort and included if they had white ethnicity 
and were older than 40 years and one or more of the following criteria: 
BMI >25 kg/m2, positive family history for type 2 diabetes mellitus, his-
tory of gestational diabetes, postprandial blood glucose >6.0 mmol/l, 
glucosuria, or use of antihypertensive medication. In total, 574 subjects 
were included and were extensively characterized with regard to their 
metabolic, cardiovascular, and lifestyle risk profiles during two visits to 
the University’s research unit. For the present study, we excluded sub-
jects with missing data on markers of adaptive and/or innate immune 
activation, IR and/or important covariates (n = 87) and those on insulin 
treatment (n = 10), and thus the total study population consisted of 
477 individuals. Subjects excluded (n = 97) did not differ from those 
included with regard to levels of waist circumference and other cardio-
vascular risk factors (data not shown).
All subjects gave written informed consent and the study was approved 
by the medical ethical committee of the Maastricht University Medical 
Centre.
anthropometrics
Height (in cm) was measured with subjects standing upright against a 
stadiometer. Body weight was measured to the nearest 100 g on elec-
tronic weight scales. BMI was calculated by dividing weight by height 
squared and expressed in kg/m2. Waist circumference was measured 
with a flexible tape at the level midway between the lowest rib and the 
iliac crest.
Ir and markers of innate immune activation
Subjects were asked to stop their lipid-lowering medication 14 days 
prior to the blood withdrawals and to refrain from eating and drinking 
after 10:00 pm in the evening before. After an overnight fast (duration 
of at least 10 h), subjects underwent a standard 75-g oral glucose toler-
ance test with venous blood sampling. Fasting plasma glucose and post-
load glucose levels were measured with a glucose hexokinase-6 method 
(ABX Diagnostics, Montpellier, France). Subjects’ glucose metabolism 
status (i.e., normal, impaired or type 2 diabetes) was defined according 
to the World Health Organization’s criteria of 1999 (25). IR was derived 
from the homeostasis model assessment (HOMA2-IR) with the use of 
software downloaded at http://www.dtu.ox.ac.uk.
High sensitivity CRP was measured in serum with a high sensitivity kit 
(Latex; Roche Diagnostics Netherlands, Almere, the Netherlands). IL-6 
was measured in EDTA plasma with a high sensitivity human Quantikine 
enzyme-linked immunosorbent assay kit (R&D systems, Minneapolis, 
MN). SAA was measured in EDTA plasma using a human invitrogen 
enzyme-linked immunosorbent assay kit (Biosource International, 
Camarillo, CA).
Markers of adaptive immune activation
Neopterin was measured using a commercially available competitive 
enzyme-linked immunosorbent assay (IBL, Hamburg, Germany), 
according to the manufacturer’s instructions. sCD25 was measured by 
a sandwich enzyme-linked immunosorbent assay using a commercially 
available antibody pair obtained from Diaclone (Diaclone Research, 
Besancon, France). Both markers were measured in serum samples. 
Both intra-assays coefficients of variation were <10%.
other risk factors
Glycated hemoglobin (HbA1c) was determined by ion-exchange high-
performance liquid chromatography (HPLC; Bio-Rad, Veenendaal, 
the Netherlands). Total and high-density lipoprotein cholesterol and 
triglycerides were measured in EDTA plasma by enzymatic methods 
(Roche, Mannheim, Germany), and low-density lipoprotein cholesterol 
was calculated according to the Friedwald formula.
Systolic and diastolic blood pressure were measured twice on each visit, 
and the mean values were used in the analyses; readings were taken on 
the right arm, with subjects in the supine position after they had rested 
for 5 min, with the use of an oscillometric device (Maxi stable 3; Speidel & 
Keller, currently: Welch Allyn, Skaneateles Falls, NY). Pulse pressure was 
calculated as systolic blood pressure−diastolic blood pressure, mean arte-
rial pressure as diastolic blood pressure+1/3 pulse pressure and hyper-
tension was defined as systolic blood pressure/diastolic blood pressure 
≥140/90 and/or the use of antihypertensive medication (26).
Smoking behavior was assessed by means of questionnaires and sub-
jects were categorized into never, ex- and current smokers. Use of blood 
pressure-, glucose- or lipid-lowering medication was also assessed by 
questionnaire. Prior cardiovascular disease was defined as the occurrence 
of myocardial infarction, bypass of the coronary arteries, percutaneous 
coronary intervention, stroke, or nontraumatic limb amputation (ascer-
tained by questionnaire), and/or the presence of signs of myocardial inf-
arction (i.e., Minnesota codes 1–1 or 1–2) or ischemia (i.e., Minnesota 
codes 1–3, 4–1, 4–2, 4–3, 5–1, 5–2, 5–3 or 7–1) on a 12-lead electrocar-
diography, and/or an ankle-brachial index <0.9 in either leg.




All analyses were carried out with the use of the Statistical Package of 
Social Sciences 15.0 for Windows (SPSS, Chicago, IL), and statistical 
significance was set at P < 0.05.
Variables with a skewed distribution (i.e., triacylglycerol, insulin, 
HOMA2-IR, CRP, IL-6, SAA and sCD25) were log10- transformed 
prior to further analyses. ANOVA or χ2 tests were used, as  appropriate, 
to  compare subjects’ characteristics across tertiles of waist circumfer-
ence. We computed a continuous “adaptive immune activation score” 
by averaging the z-scores (i.e., (subject’s value−group’s mean)/group’s 
s.d.) of neopterin and log10sCD25, and an “innate immune activation 
score” by averaging the z-scores of log10CRP, log10IL-6, and log10SAA. 
These scores enable a more robust characterization of the mecha-
nisms represented and help overcome the problem of misclassifica-
tion, the latter often leading to an underestimation of the strength of 
the associations when each marker is analyzed separately.
Simple and multiple mediation analyses. When simple and/
or multiple mediation hypotheses are entertained, as in the present 
study, the magnitude of the associations linking all the variables of 
interest need to be established first (27). We have therefore used mul-
tiple linear regression analyses to ascertain: (i) the association between 
waist circumference (X) and the adaptive immune activation score 
(Y)—path c; (ii) the association between X and each of the mediators 
(M(s)) proposed, i.e., innate immune activation score and IR—path(s) 
a; and (iii) the association between the M(s) and Y, when controlling 
for X and the other mediator in multiple mediation models—path(s) 
b. Path c thus represents the total “effect” of X on Y, which can be 
apportioned into the direct “effects” of X on Y (path c′) + the indirect 
effect of X on Y through the M(s) (paths ab or c–c′)—Figure 1a,b, 
for simple mediation and Figure 1a,c for multiple mediation mod-
els (28–30). All these analyses were performed with adjustments for 
the following covariates: age, sex, glucose metabolism status, smoking 
status and prior cardiovascular disease, and also for other risk factors, 
i.e., HbA1c, mean arterial pressure, total-to-high-density lipoprotein 
cholesterol ratio and triacylglycerol. Results hereby obtained were 
reported as standardized regression coefficients (β) and respective 
95% confidence intervals to enable comparison of the strength of the 
associations investigated.
Traditionally, mediation is considered to be present when the 
strength of the association between X and Y (path c) decreases by 
a nontrivial amount after further adjustment for the M(s)—path c′; 
the ratio of the indirect to the total “effects” (i.e., ab/c) is then often 
interpreted as the proportion of the total effect that is mediated by the 
mediator(s) (27,28). However, and according to recent recommenda-
tions regarding mediation data analyses procedures, this concept is 
flawed in situations when c < ac (yielding proportion >1), c and ab 
have different directions (yielding negative proportions), c = 0 (yield-
ing a situation in which the proportion is undefined) or when c is 
close to 0 (when any trivial mediation may seem massive) (28,31). 
Instead, a better approach is to estimate the magnitude of the indi-
rect “effect(s)” and the respective 95% confidence intervals, thereby 
enabling the testing of whether such “effects” differ significantly from 
0 (29). In addition, when multiple mediators are investigated, as in 
the present case, contrasting the specific indirect “effects” attribut-
able to one vs. the other mediator is of interest (30). Accordingly, we 
computed bootstrapped (bias-corrected) confidence intervals (5,000 
samples) for the size of the specific mediation “effects” using SPSS 
macros provided by Preacher & Hayes (30). These analyses enabled 
the appreciation of whether any of the proposed mediators exerts 
a predominant role in the association investigated, thus contribut-
ing to a better understanding of the operative pathophysiological 
 mechanisms (28,30,31).
results
Table 1 shows the general characteristics of the study popu-
lation across tertiles of waist circumference. Subjects with 
increasing levels of waist circumference were characterized by 
a more adverse cardiovascular risk profile. Levels of markers 
of adaptive and innate immune activation and their scores, as 
well as HOMA2-IR, were also significantly increased across 








































Figure 1 Illustration of a simple mediation model (a,b) and a 
multiple mediation model with two mediators (M1 and M2) (a,c), in the 
context of the present study. (a) Total “effect” of waist circumference 
(X: independent variable) on adaptive immune activation score (Y: 
dependent variable)—path c. (b) Waist circumference is hypothesized 
to exert indirect “effects” on adaptive immune activation score through 
a given mediator (M: innate immune activation score or insulin 
resistance—log10HOMA2-IR); this figure thus represents both the 
direct effect of X on Y (path c′) and the indirect effect of X on Y through 
M is defined by the product of the 2 paths linking X to Y through 
that mediator (path ab). (c) Waist circumference is hypothesized to 
exert indirect “effects” on adaptive immune activation score through 
both innate immune activation score (M1) and insulin resistance—
log10HOMA2-IR (M2); this figure thus represents both the direct 
effect of X on Y (path c′) and the indirect effect of X on Y through the 
mediators. The specific indirect effect of X on Y through M1 is defined 
by the product of the two paths linking X to Y through that mediator, 
i.e., a1b1; similarly, the specific indirect effect of X on Y through M2 
is defined by the product of the two paths linking X to Y through that 
mediator, i.e., a2b2. The total indirect effects of X on Y is the sum of the 
two specific indirect effects, i.e., a1b1 + a2b2; The total effect of X on Y is 
thus the sum of the direct effect and all of the indirect effects: c = c′ + 
a1b1 + a2b2; all analyses were adjusted for the following covariates: 
age, sex, glucose metabolism status, smoking status, mean arterial 
pressure, glycated hemoglobin (HbA1c), total-to-high-density lipoprotein 
cholesterol ratio and triglycerides. HOMA-IR, insulin resistance derived 
from the homeostasis model assessment.
obesity | VOLUME 19 NUMBER 8 | aUgUst 2011 1693
articles
epidemiology
associations between waist circumference and markers  
of adaptive and innate immune activation and Ir
After adjustments for age, sex, glucose metabolism and smok-
ing status, waist circumference was positively associated with 
neopterin (β = 0.08 (95% confidence intervals: −0.01 to 0.18), 
P = 0.090) and sCD25 (β = 0.16 (0.06 to 0.25), P = 0.002), as 
well as the adaptive immune activation score (β = 0.12 (0.04 to 
0.20), P = 0.002) (model 1) (Table 2). Further adjustments for 
other risk factors did not materially affect these associations 
(model 2). Waist circumference was also positively associated 
with the innate immune activation score (β = 0.24 (0.17 to 
0.31), P < 0.001) and each of its constituent markers (i.e., CRP, 
IL-6, and SAA), as well as with HOMA2-IR (β = 0.55 (0.48 
to 0.62), P < 0.001) (model 1). Again, further adjustments for 
other risk factors did not change these associations appreciably 
(β = 0.25 (0.18 to 0.32), and β = 0.49 (0.42 to 0.56), respectively, 
both P < 0.001) (model 2).
associations between (markers of) innate immune activation 
and Ir and (markers of) adaptive immune activation
The innate immune activation score (and each of its constitu-
ent markers) were positively and significantly associated with 
table 1 Baseline characteristics of the study population according to tertiles of waist circumference
Tertiles of waist circumference
P for linear trendT1 (n = 163) T2 (n = 154) T3 (n = 160)
Sex, % men 46.6 70.1 75.0 <0.001
Age, years 58.8 (7.4) 59.5 (7.1) 60.1 (6.3) 0.088
BMI, kg/m2 25.0 (2.3) 28.0 (2.0) 32.3 (4.0) <0.001
Waist circumference,a cm 87.4 (6.1) 98.4 (2.6) 111.8 (7.4) <0.001
Systolic blood pressure, mm Hg 135.4 (19.4) 141.6 (19.1) 143.7 (16.5) <0.001
Diastolic blood pressure, mm Hg 78.9 (8.6) 81.8 (9.3) 85.2 (8.3) <0.001
Pulse pressure, mm Hg 56.5 (14.6) 59.8 (15.6) 58.5 (14.3) 0.225
Mean arterial pressure, mm Hg 97.7 (11.3) 101.7 (11.2) 104.7 (10.1) <0.001
Antihypertensive treatment, % 30.7 28.6 48.8 <0.001
Hypertension, % 44.2 66.2 73.8 <0.001
Total cholesterol, mmol/l 5.19 (1.05) 5.30 (0.95) 5.11 (0.83) 0.457
LDL-cholesterol, mmol/l 3.23 (0.86) 3.43 (0.81) 3.21 (0.78) 0.870
HDL-cholesterol, mmol/l 1.33 (0.38) 1.18 (0.30) 1.07 (0.28) <0.001
Total-to-HDL cholesterol ratio 4.15 (1.32) 4.81 (1.61) 5.08 (1.43) <0.001
Triacylglycerol, mmol/l 1.0 (0.8–1.6) 1.4 (1.0–1.9) 1.7 (1.3–2.2) <0.001
Lipid-lowering medication, % 17.2 13.6 20.6 0.416
Fasting plasma glucose, mmol/l 5. 61(1.02) 5.93 (1.14) 6.38 (1.52) <0.001
Glycated hemoglobin, % 5.78 (0.62) 5.84 (0.61) 6.14 (0.89) <0.001
Fasting plasma insulin, pmol/l 47 (38–57) 59 (44–84) 83 (61–128) <0.001
Insulin resistance (HOMA2-IR) 0.90 (0.72–1.09) 1.14 (0.84–1.64) 1.62 (1.20–2.48) <0.001
Glucose-lowering medication, % 6.1 10.4 15.6 0.006
Glucose metabolism status
 NGM/IGM/DM2, % 64.4/21.5/14.1 57.8/20.8/21.4 41.3/25.0/33.8 <0.001
Smoking status
 Never/ex-/current smoker, % 35.0/41.1/23.9 20.1/57.8/22.1 28.1/56.3/15.6 0.856
Prior cardiovascular disease, % 17.2 27.3 34.4 <0.001
C-reactive protein, mg/l 1.7 (1.0–3.8) 2.6 (1.5–4.3) 3.2 (1.9–5.7) <0.001
Interleukin-6, pg/ml 1.1 (0.8–1.7) 1.3 (1.0–2.0) 1.8 (1.2–2.7) <0.001
Serum amyloid A, µg/ml 6.4 (3.7–14.1) 8.0 (4.7–13.7) 8.0 (4.5–15.1) 0.099
Neopterin, nmol/l 5.88 (1.81) 6.24 (2.05) 6.56 (2.59) 0.005
Soluble CD25, µg/ml 2.33 (1.76–3.16) 2.64 (2.04–3.23) 2.61 (1.97–3.37) 0.021
Data are percentages, means (standard deviations) or median (inter-quartile ranges).
DM2, type 2 diabetes; HDL, high-density lipoprotein; HOMA2-IR, insulin resistance from the homeostasis model assessment; IGM, impaired glucose metabolism; 
LDL, low-density lipoprotein; NGM, normal glucose metabolism; T1, lowest tertile; T2, middle tertile; T3, highest tertile.
aSpecific mean (s.d.) values in men were 89.4 (4.5), 98.4 (2.5), and 112.2 (7.7), and in women 85.6 (6.8), 98.5 (2.7), and 110.7 (6.3), for T1, T2, and T3, respectively.
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neopterin, sCD25, and the adaptive immune activation score 
(Table 3). These associations were independent of age, sex, 
glucose metabolism, smoking status, prior cardiovascular dis-
ease (model 1), other risk factors (model 2), but also of waist 
circumference (model 3) and HOMA2-IR (model 4a): β = 0.31 
(0.21 to 0.40), P < 0.001, for the association between the innate 
and the adaptive immune activation scores. After all adjust-
ments (model 4b), HOMA2-IR was also positively and signifi-
cantly associated with the adaptive immune activation score: 
β = 0.11 (0.02 to 0.21), P = 0.021.
Mediating role of innate immune activation and/or Ir  
in the association between waist circumference  
and adaptive immune activation
The strength of the association between waist circumference 
and the adaptive immune activation score (β = 0.118 (0.038 
to 0.197)) was attenuated and no longer significant when fur-
ther adjusted for innate immune activation score (to β = 0.038 
(−0.041 to 0.118), P = 0.346) or HOMA2-IR (to β = 0.048 
(−0.044 to 0.141), P = 0.304), respectively (Table 4). The indi-
rect associations of waist circumference on adaptive immune 
activation score through the innate immune activation score 
or through HOMA2-IR were both significant: β = 0.079 
(0.050 to 0.117), P < 0.001 and β = 0.069 (0.021 to 0.128), 
P = 0.011, respectively—simple mediation analyses. When 
adjustments for both mediators were considered simultane-
ously, the association between waist circumference and the 
adaptive immune activation score was completely abolished 
to β = −0.013 (−0.104 to 0.077), P = 0.777, and thus the total 
indirect associations through the mediators had a magnitude 
of 0.131 (0.077 to 0.192), P < 0.001. Analyses performed in 
order to tease apart the specific relative contribution of the 
immune activation score and of HOMA2-IR as mediators 
of this association showed that these had a magnitude of 
β = 0.076 (0.048 to 0.115), P < 0.001 and β = 0.054 (0.006 to 
0.111), P = 0.041, or 58% vs. 42%, respectively, which were not 
statistically different from each other, however (β = −0.022 
(−0.087 to 0.043), P = 0.508).
additional analyses
We also conducted analyses with BMI, instead of waist cir-
cumference, as main determinant of adaptive immune activa-
tion. All associations, including the mediation role of innate 
immune activation and HOMA2-IR, were very similar to 
those reported herein (data not shown). low-density lipopro-
tein–lowering drugs including statins have been demonstrated 
to exert immunosuppressive activities (reviewed in ref. 32). 
However, none of the associations described herein changed 
materially after further adjustments for the use of lipid-low-
ering medication (data not shown). Replacing mean arterial 
pressure by systolic blood pressure or hypertension as a cov-
ariate in our models also did not change any of the estimates 
reported (data not shown).
dIscussIon
The main findings of the present study are threefold. First, 
waist circumference, a marker of abdominal fat mass, is asso-
ciated not only with higher systemic levels of markers of innate 
immune activation and IR but also with higher levels of mark-
ers of adaptive immune activation. Second, the association 
between abdominal fat and adaptive immune activation is 
completely explained, i.e., mediated, by abdominal fat–related 
elevations in innate immune activation and IR. Finally, each 
of these mediators represents independent pathways of simi-
lar importance linking abdominal fat to adaptive immune 
activation.
Using a flow-cytometric approach, adaptive immune activa-
tion has recently been demonstrated in morbidly obese study 
table 2 associations of waist circumference with markers of adaptive and innate immune activation and with insulin resistance
Dependent variables
Model 1 Model 2
β 95% CI P value β 95% CI P value
Markers of adaptive immune activation
 Neopterin 0.08 −0.01; 0.18 0.090 0.09 −0.01; 0.19 0.084
 Log10sCD25 0.16 0.06; 0.25 0.002 0.15 0.05; 0.25 0.004
 Adaptive immune activation score 0.12 0.04; 0.20 0.002 0.12a 0.04; 0.20 0.004
Markers of innate immune activation
 Log10CRP 0.33 0.24; 0.42 <0.001 0.33 0.23; 0.42 <0.001
 Log10IL-6 0.23 0.14; 0.32 <0.001 0.25 0.15; 0.35 <0.001
 Log10SAA 0.16 0.07; 0.26 0.001 0.17 0.07; 0.27 0.001
 Innate immune activation score 0.24 0.17; 0.31 <0.001 0.25b 0.18; 0.32 <0.001
Insulin resistance
 Log10HOMA2-IR 0.55 0.48; 0.62 <0.001 0.49
c 0.42; 0.56 <0.001
Model 1, adjusted for age, sex, glucose metabolism, smoking status and prior cardiovascular disease. Model 2, model 1 + adjustments for mean arterial pressure, gly-
cated hemoglobin (HbA1c), total-to-high-density lipoprotein cholesterol ratio and log10 triglycerides. The boldface values are used to construct table 4.
β, standardized regression coefficient; indicates change in dependent variable (in s.d.) per s.d. increase in waist circumference; CI, confidence interval; CRP, C-reactive 
protein; HOMA2-IR, insulin resistance derived from the homeostasis model assessment; IL-6, interleukin-6; SAA, serum amyloid A; sCD25, soluble CD25.
aPath c. bPath a1. 
cPath a2 in multiple mediation analyses (see Figure 1).
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subjects (33). Positive associations between measures of (cen-
tral) obesity and neopterin have previously been shown in a 
large cohort of apparently healthy individuals (34) and two 
small studies on healthy and obese individuals (35,36). We 
have now confirmed but also extended those findings to yet 
another marker of adaptive immune activation—sCD25—in a 
relatively large cohort of individuals at increased risk of type 2 
diabetes and cardiovascular disease. In addition, this is the first 
study that has investigated not only the association between 
abdominal fat and markers of adaptive immune activation, 
but also potential underlying mechanisms explaining any such 
associations.
Recent papers suggest that T lymphocytes are critically 
involved in the regulation of adipose tissue inflammation. 
Nishimura and colleagues showed that adipose tissue CD8+ 
T cells have an essential role in macrophage recruitment (12). 
CD4+ effector cells can generally be divided into proinflamma-
tory cells (T helper (Th)1, Th17), and anti-inflammatory cells 
and regulatory sublineages (Th2, Tregs). In adipose tissue in 
lean mice, Th2 and Treg cells predominate and these cells seem 
to be critically involved in the regulation of body weight, adi-
pose tissue inflammation and IR (13,14). In both human and 
mice, there is a shift in adipose tissue T-cell populations so that 
CD8+ and Th1 T cells dominate (13). Th1-derived interferon-γ 
is classically known to activate macrophages. This process may 
augment proinflammatory cytokine (like IL-1β, tumor necro-
sis factor-α, and IL-6) production in the adipose tissue and 
these molecules may then be released into the systemic circu-
lation. Indeed, the present study confirms that serum levels of 
tumor necrosis factor-α, IL-6, and acute phase reactants such 
as CRP and SAA are higher in individuals with greater levels 
of (central) obesity (15).
The involvement of innate and adaptive immune compo-
nents in the inflammatory process at the local level (i.e., in 
adipose tissue) may differ from that at the systemic circula-
tion level. In adipose tissue, adaptive immune cells (T cells) 
appear to initiate and regulate innate immune cells and hereby 
IR, whereas in the systemic circulation the adaptive immune 




Adaptive immune  
activation score
β 95% CI P value β 95% CI P value β 95% CI P value
Markers of innate immune activation
 Log10CRP 1 0.16 0.07; 0.25 0.001 0.24 0.15; 0.33 <0.001 0.20 0.13; 0.27 <0.001
2 0.16 0.07; 0.25 0.001 0.21 0.12; 0.30 <0.001 0.19 0.11; 0.26 <0.001
3 0.15 0.05; 0.25 0.003 0.19 0.09; 0.28 <0.001 0.17 0.09; 0.24 <0.001
4a 0.14 0.04; 0.24 0.004 0.18 0.08; 0.27 <0.001 0.16 0.09; 0.24 <0.001
 Log10IL-6 1 0.31 0.22; 0.40 <0.001 0.28 0.18; 0.37 <0.001 0.29 0.22; 0.36 <0.001
2 0.31 0.22; 0.40 <0.001 0.25 0.16; 0.34 <0.001 0.28 0.21; 0.35 <0.001
3 0.31 0.22; 0.40 <0.001 0.23 0.14; 0.33 <0.001 0.27 0.20; 0.34 <0.001
4a 0.30 0.21; 0.40 <0.001 0.23 0.13; 0.32 <0.001 0.26 0.19; 0.34 <0.001
 Log10SAA 1 0.15 0.06; 0.24 0.001 0.11 0.02; 0.20 0.021 0.13 0.06; 0.20 0.001
2 0.15 0.06; 0.24 0.001 0.11 0.02; 0.20 0.018 0.13 0.06; 0.21 <0.001
3 0.14 0.05; 0.24 0.002 0.09 0.00; 0.19 0.049 0.12 0.05; 0.19 0.002
4a 0.14 0.05; 0.23 0.004 0.08 −0.01; 0.17 0.088 0.11 0.04; 0.18 0.004
 Innate immune activation score 1 0.34 0.23; 0.46 <0.001 0.35 0.23; 0.47 <0.001 0.35 0.26; 0.44 <0.001
2 0.35 0.23; 0.46 <0.001 0.32 0.20; 0.44 <0.001 0.33 0.24; 0.42 <0.001
3 0.35 0.22; 0.47 <0.001 0.29 0.17; 0.42 <0.001 0.32a 0.22; 0.41 <0.001
4a 0.34 0.22; 0.46 <0.001 0.28 0.16; 0.40 <0.001 0.31c 0.21; 0.40 <0.001
Insulin resistance
 Log10HOMA2-IR 1 0.12 0.02; 0.21 0.021 0.22 0.13; 0.32 <0.001 0.17 0.09; 0.25 <0.001
2 0.12 0.02; 0.23 0.022 0.21 0.11; 0.32 <0.001 0.17 0.08; 0.25 <0.001
3 0.10 −0.02; 0.23 0.102 0.18 0.06; 0.30 0.004 0.14b 0.04; 0.24 0.004
4b 0.07 −0.05; 0.19 0.257 0.15 0.03; 0.27 0.013 0.11d 0.02; 0.21 0.021
Model 1, adjusted for age, sex, glucose metabolism, smoking status and prior cardiovascular disease. Model 2, model 1 + adjustments for mean arterial pressure, 
glycated hemoglobin (HbA1c), total-to-high-density lipoprotein cholesterol ratio and log10 triglycerides; Model 3, model 2 + adjustment for waist circumference; Model 4a, 
model 3 + adjustment for log10HOMA2-IR; Model 4b, model 3 + adjustment for innate immune activation score. The boldface values are used to construct table 4.
β, standardized regression coefficient; indicates change in dependent variable (in s.d.) per s.d. increase in independent variable; CI, confidence interval; CRP, C-reactive 
protein; HOMA2-IR, insulin resistance derived from the homeostasis model assessment; IL-6, interleukin-6; SAA, serum amyloid A.
aPath b1 and 
bpath b2 in simple mediation analyses (see Figure 1); 
cPath b1 and 
dpath b2 in multiple mediation analyses (see Figure 1).
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system may get involved as a result of adipose-related increases 
in innate immune activation and/or IR. Our data are consist-
ent with this hypothesis which can find some support from the 
following observations. Proinflammatory cytokines, derived 
from innate immune cells, may lower the threshold for periph-
eral T-cell activation (37). In addition, maturation, and conse-
quently the ability of antigen-presenting cells to elicit a T-cell 
response, may be enhanced in an inflammatory microenviron-
ment (38). Nevertheless, T-cell activation is critically depend-
ent on specific triggering of the T-cell receptor. The triggers 
for the observed obesity-associated systemic T-cell activation 
remain speculative although there is abundant expression of 
candidate T-cell–triggering antigens in obese subjects.
IR was the other important mediator in the observed asso-
ciation between abdominal fat and adaptive immune activa-
tion. Besides the regulation of glucose and lipid metabolism, 
a number of other biological functions have been assigned to 
insulin, including an anti-inflammatory function. The effects 
of insulin on T-cell function have not yet been unraveled, 
although Viardot et al. demonstrated that insulin can direct 
polarization of effector T cells toward a Th2 phenotype (39). 
The inability of T cells to respond to insulin, e.g., T-cell IR, 
might result in a more Th1-polarized T-cell compartment. 
Since neopterin is a product of interferon-γ–activated macro-
phages, the higher neopterin levels in subjects in the highest 
tertile of waist circumference suggest that the Th1 T-cell com-
partment in these subjects is in a more activated state. The low 
level of insulin sensitivity in this group of subjects might have 
contributed to this.
The role of the adaptive immune system in the pathogen-
esis of obesity-related vascular complications remains specu-
lative. Guzik et al. showed that T cells and T-cell–derived 
tumor necrosis factor-α and IL-17 are involved in the patho-
genesis of hypertension (40,41). In addition, subsets of T cells 
have been demonstrated to play critical roles in atherogene-
sis (reviewed in ref. 42). The presence of activated T cells in 
table 4 association between waist circumference and adaptive immune activation score, and the total and specific mediation 
role of innate immune activation and insulin resistance herein
Path Description
Simple mediation analyses Multiple mediation analyses
By innate immune  
activation score By log10HOMA2-IR
By innate immune 




(%)aβ 95% CI P value β 95% CI P value β 95% CI P value




0.004 0.118 0.038; 0.197 0.004 0.118 0.038; 
0.197
0.004 —




<0.001 — — — 0.248 0.175; 
0.321
<0.001 —
a2 Waist → log10HOMA2-IR — — — 0.490 0.416; 0.564 <0.001 0.490 0.416; 
0.564
<0.001 —
b1 Innate immune activation 




<0.001 — — — 0.307 0.212; 
0.402
<0.001 —
b2 Log10HOMA2-IR → 
adaptive immune  
activation score 
— — — 0.141 0.044; 0.238 0.005 0.111 0.017; 
0.204
0.021 —
c′ Waist → adaptive immune 
activation score  
(– mediator(s), i.e., c–ab)′
0.038 −0.041; 
0.118








<0.001 0.069 0.021; 0.128 0.011 0.131 0.077; 
0.192
<0.001 —
 Specific indirect association  
 through innate immune  
 activation score (a1b1)
— — — — — — 0.076 0.048; 
0.115
<0.001 58%
 Specific indirect association  
 through log10HOMA2-IR (a2b2)
— — — — — — 0.054 0.006; 
0.111
0.041 42%
Comparison of specific indirect  
associations through innate  
immune activation score vs. 
log10HOMA2-IR
— — — — — −0.022 −0.087; 
0.043
0.508 —
All associations are adjusted for the following covariates: age, sex, glucose metabolism, smoking status, prior cardiovascular disease (CVD), mean arterial pressure, 
glycated hemoglobin (HbA1c), total-to-high-density lipoprotein cholesterol ratio and log10 triglycerides.
β, are standardized regression coefficients; CI, confidence interval; HOMA2-IR, insulin resistance derived from the homeostasis model assessment.
aCalculated as proportion of the total indirect effects attributed to the specific mediators: i.e., 0.076/0.131 × 100 for innate immune activation and 0.054/0.131 × 100 
for log10HOMA2-IR.
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atheromatous lesions implies that these cells are involved in 
a specific immune reaction, probably directed against locally 
expressed or formed (auto)antigens, e.g., oxidized low-density 
lipoprotein (43). T lymphocytes can influence atherogenesis 
progression by regulating the magnitude of the inflammatory 
response within the plaque, as well as plaque stability and the 
propensity for thrombus formation. Further research in this 
area is nevertheless needed.
Limitations of the present study have to be taken into 
account. First, the separation of markers into markers of innate 
or adaptive immune activation is not absolute. IL-6 can also be 
made by T cells, but macrophages and adipocytes are primary 
sources. In addition, sCD25 is predominantly released from 
activated T cells, although it may also be released from acti-
vated B cells and natural killer cells. Upon activation, Th1 cells 
secrete large amounts of interferon-γ, which will subsequently 
trigger neopterin release from monocytes (44). Although 
monocytes belong to the innate immune system, neopterin is 
not released in the absence of T-cell activation. Consequently, 
neopterin is considered to be a marker of adaptive immune 
cell activation. Second, our research questions were addressed 
within the context of a cross-sectional study design, which 
hinders definite conclusion in terms of causality. Indeed, 
although we hypothesized and tested “causal models” link-
ing abdominal fat to (markers of) adaptive immune activation 
through abdominal fat–related increases in innate immune 
activation and/or IR pathways, we cannot discard the possibil-
ity of reverse causation. In other words, associations between 
abdominal fat and innate inflammation and/or IR could (also) 
be explained, i.e., mediated, by abdominal fat–related increases 
in adaptive immune activation. Indeed, additional analyses 
testing these reverse causation models also showed that these 
pathways could be operative, but with much smaller mediating 
magnitudes (13 and 3%, respectively) than the ones reported 
under our primary hypothesis (data not shown). Longitudinal 
and time-lagged data are thus needed to further investigate the 
directions of the associations tested. Finally, our study popu-
lation consisted of middle-aged and older white individuals 
at high risk for type 2 diabetes and cardiovascular disease. 
Caution is thus needed in the extrapolation of our findings to 
other populations (i.e., younger and/or healthier and of other 
ethnicities).
In conclusion, on the basis of multiple mediation analy-
ses, our data suggest that the associations between abdomi-
nal obesity and adaptive immune activation could be due to 
obesity-related innate immune activation and IR. Further 
research is needed to gain more insight into the triggers of the 
observed abdominal fat–related T-cell activation and to eluci-
date the role of the adaptive immune system, and more specifi-
cally of T cells, in the pathogenesis of obesity-related vascular 
complications.
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